CDC Scores Poorly on Biosafety

In the wake of numerous safety breaches at the federal agency, a new report finds US Centers for Disease Control and Prevention oversight “inconsistent and insufficient at multiple levels.”

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA“Safety is not integrated into strategic planning and is not currently part of the CDC [US Centers for Disease Control and Prevention] culture, enterprise-wide.” This is the conclusion of a new report evaluating the federal agency’s internal protocols.

The last nine months have been a public relations nightmare for the agency. In two separate incidents last summer, samples of live Bacillus anthracis were accidentally shipped to labs ill-equipped to handle the pathogen, and the CDC’s influenza lab mistakenly sent samples of the highly pathogenic H5N1 to a Department of Agriculture facility (instead of benign avian influenza virus). Then, in late December, another incorrect transfer of samples risked exposing a lab technician to Ebola.

Following these safety breaches, the CDC announced that it would hire a lab safety chief to oversee the handling of such dangerous pathogens, and brought an external work group of 11 biosafety and laboratory science experts in to assess its safety protocols. The group’s report—dated January 13 but just posted ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio